2006
DOI: 10.2337/diabetes.55.01.06.db05-0648
|View full text |Cite
|
Sign up to set email alerts
|

Muraglitazar, a Novel Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, Improves Diabetes and Other Metabolic Abnormalities and Preserves β-Cell Function in db/db Mice

Abstract: 1Muraglitazar, a novel dual (␣/␥) peroxisome proliferatoractivated receptor (PPAR) activator, was investigated for its antidiabetic properties and its effects on metabolic abnormalities in genetically obese diabetic db/db mice. In db/db mice and normal mice, muraglitazar treatment modulates the expression of PPAR target genes in white adipose tissue and liver. In young hyperglycemic db/db mice, muraglitazar treatment (0.03-50 mg ⅐ kg ؊1 ⅐ day ؊1 for 2 weeks) results in dose-dependent reductions of glucose, ins… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
42
0

Year Published

2006
2006
2018
2018

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 82 publications
(43 citation statements)
references
References 43 publications
1
42
0
Order By: Relevance
“…Beneficial metabolic effects of glitazars have been demonstrated in animal studies [9,10,12,26,27,28]. …”
Section: Discussionmentioning
confidence: 99%
“…Beneficial metabolic effects of glitazars have been demonstrated in animal studies [9,10,12,26,27,28]. …”
Section: Discussionmentioning
confidence: 99%
“…It has been postulated that the trend towards increasing weight gain with TZD's treatment is probably due to either adipogenesis or increased plasma volume or both (Harrity et al, 2006). Rosiglitazone at its therapeutic dose shows a significant increase in plasma volume and subsequent decrease in haematocrit and haemoglobin as a result of increased sodium reabsorption in the collecting ducts of kidney (Arakawa et al, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…Insulin levels were measured by radioimmunoassay. Hepatic triglyceride content was measured by spectrophotometry and expressed as TG mg/g wet liver weight according to published methods (Harrity et al, 2006).…”
Section: Biochemical Assaysmentioning
confidence: 99%